# MyPathway (NCT02091141)

> My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02091141
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Neoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer; Bladder Cancer
- Interventions: Trastuzumab; Pertuzumab; Erlotinib; Vemurafenib; Cobimetinib; Vismodegib; Alectinib; Atezolizumab
- Enrollment: 673
- Primary outcome: Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator
- Primary outcome: Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)

## Indexed commentary on MyPathway so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 30
- X threads: 22
- YouTube: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mypathway-nct02091141

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02091141", "email": "<work email>"}; the inbox owner confirms by the emailed link.